|
沙利度胺对血液肿瘤患者内皮细胞功能的影响 |
|
HOGLUND P.Clinical pharmacology of thalidomide[J].Eur J Clin Pharmacol,2001,57(5):365376.
[2] RAJKUMAR SV.Current status of thalidomide in the treatment of cancer[J].Oncology (Huntingt),2001,15(7):867874.
[3] SEZER O,NIEMOLLER K,EUCKER J,et al.Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma[J].Ann Hematol,2000,24:574576.
[4] CHEN Y,MCCARRON RM,GOLECH S,et al.ET1 and NOmediated signal transduction pathway in human brain capillary endothelial cells[J].Am J Physial Cell Physiol,2003,9:284,243.
[5] MEIERHOFER C,DUNZENDORFER S,WIEDERMANN C J.Theoretical basis for the activity of thalidomide[J].BioDrugs,2001,15(10):681703.
[6] 朱 琦,胡钧培,叶为德。沙利度胺对多发性骨髓瘤患者止凝血功能的影响[J].血栓和止血学,2006,12(3):111113.
上一页 [1] [2] [3] [4] 上一个医学论文: 体外血小板流动腔研究方法的建立和应用 下一个医学论文: 习惯性流产的抗凝血酶原抗体IgG IgM检测的初步应用
|
|
|
|
|
|
|